Dogan Zeynal, Filik Levent, Ergül Bilal, Sarikaya Murat
Department of Gastroenterology, Ankara Education and Research Hospital, Altındağ, Ankara, Turkey.
Saudi J Gastroenterol. 2015 Nov-Dec;21(6):396-9. doi: 10.4103/1319-3767.164186.
BACKGROUND/AIM: Hepatic steatosis may influence the response to antivirals in chronic hepatitis B patients. This study aimed to compare the efficacy of entecavir and tenofovir in nucleos(t) ide-naive chronic hepatitis B patients with hepatosteatosis during 48 weeks of therapy.
We retrospectively reviewed our data for chronic hepatitis B patients. Nucleos(t) ide-naive patients with hepatosteatosis who took entecavir or tenofovir for at least 48 weeks were included. We compared entecavir and tenofovir after 48 weeks of therapy with respect to virological, biochemical, and serological responses in patients with hepatosteatosis.
Of the 63 patients, 21 received entecavir and 42 received tenofovir. Baseline characteristics of the patients were similar except for body mass index. At the end of week 48, there was no statistically significant difference between tenofovir and entecavir treatment regarding total HBV-DNA negativity and alanine transferase normalization in patients with chronic hepatitis B and hepatosteatosis.
Entecavir and tenofovir are similarly effective in nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis after 48 weeks of therapy.
背景/目的：肝脂肪变性可能影响慢性乙型肝炎患者对抗病毒药物的反应。本研究旨在比较恩替卡韦和替诺福韦在初治的合并肝脂肪变性的慢性乙型肝炎患者治疗48周期间的疗效。
我们回顾性分析了慢性乙型肝炎患者的数据。纳入了初治的合并肝脂肪变性且服用恩替卡韦或替诺福韦至少48周的患者。我们比较了治疗48周后恩替卡韦和替诺福韦在合并肝脂肪变性患者中的病毒学、生化和血清学反应。
63例患者中，21例接受恩替卡韦治疗，42例接受替诺福韦治疗。除体重指数外，患者的基线特征相似。在第48周结束时，对于慢性乙型肝炎合并肝脂肪变性患者，替诺福韦和恩替卡韦治疗在HBV-DNA总体转阴率和丙氨酸转氨酶正常化方面无统计学显著差异。
治疗48周后，恩替卡韦和替诺福韦在初治的合并肝脂肪变性的慢性乙型肝炎患者中疗效相似。
